| Title |
Ovarian cancer: emerging molecular-targeted therapies
|
|---|---|
| Published in |
Biologics: Targets & Therapy, June 2012
|
| DOI | 10.2147/btt.s24155 |
| Pubmed ID | |
| Authors |
Carole Sourbier |
| Abstract |
With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Pakistan | 1 | 3% |
| Unknown | 27 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 21% |
| Student > Ph. D. Student | 6 | 21% |
| Researcher | 6 | 21% |
| Student > Postgraduate | 4 | 14% |
| Student > Master | 3 | 10% |
| Other | 3 | 10% |
| Unknown | 1 | 3% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 13 | 45% |
| Medicine and Dentistry | 8 | 28% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Computer Science | 1 | 3% |
| Physics and Astronomy | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 2 | 7% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2013.
All research outputs
#16,048,009
of 25,374,647 outputs
Outputs from Biologics: Targets & Therapy
#176
of 284 outputs
Outputs of similar age
#108,770
of 179,216 outputs
Outputs of similar age from Biologics: Targets & Therapy
#8
of 9 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,216 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.